



FOR IMMEDIATE RELEASE

FLAMMA GROUP acquires additional API site in Italy

Chignolo D'Isola, Bergamo, Italy – March 16, 2022 – The **Flamma Group** (“Flamma”), a global, fully integrated company producing and commercializing small molecule Active Pharmaceutical Ingredients (APIs) for the life science industry as well as a preeminent Contract Development and Manufacturing Organization (CDMO) of New Chemical Entities (NCEs) and late stage intermediates for the Innovator Companies, announced that it will acquire a third API manufacturing site in Italy as of April 2022.

Flamma reached an agreement earlier this year with Teva Group for acquiring Sicor Bulciago site located in Lecco, Italy, only 30 km from Flamma’s headquarters. It has a long history of established cGMP manufacturing of pharmaceutical materials including APIs. It has more than 600 cubic meters of manufacturing capacity and has been previously inspected by the FDA, the Italian Ministry of Health (AIFA), the Brazilian Health Regulatory Agency (ANVISA) and has been accredited by the PDMA (Japan).

This acquisition strengthens and expands Flamma’s manufacturing services as a fully integrated CDMO that is privately held and family run since 1950. The ability to integrate Bulciago into the Flamma Group will be enhanced by the proximity of the site as well as the familiarity of numerous current Flamma employees who previously worked at the site.

Dr. Gianpaolo Negrisoni, Chief Executive Officer of Flamma, noted, “We are extremely happy to bring the Bulciago site into the Flamma Group of companies. This allows us to rapidly enhance our CMC offerings to our customers by providing further flexibility between sites. Having the ability to produce more generic APIs in Italy is in line with the European Pharmaceutical strategy aiming to reshore by having a more robust and resilient supply chain in the pharmaceutical sector that is not totally dependent on Asia.”

Negrisoni adds, “For this reason, we could not allow this factory, so important, with a history of more than 50 years and a production and technological tradition of great value, to disappear. We are very proud to be able to guide its rebirth towards very significant production goals.”

“With Bulciago, Flamma adds 600 cubic meters of available manufacturing capacity bringing our total capacity in Italy to over 900 cubic meters. This goes along with the soon to be 600 cubic meters of manufacturing capacity in China as we begin expansion of Flamma Honkai this year”, added Negrisoni.

Flamma has been busy over the past few years with the addition of Flamma USA in Malvern, PA just outside Philadelphia to handle early stage small molecule projects. The soon to be



completed R&D expansion at Chignolo that will quadruple its R&D space there and allow for not only more R&D capabilities but allows for additional analytical resources in the building that was shared between the two groups. Flamma will invest over € 150M (\$167M) over the next three years for increasing capacity and the addition of new technologies across its sites in Italy, China and the USA.

“This is an exciting time at Flamma as we continue to grow to over 1,500 cubic meters of total manufacturing capacity yet still maintain our roots as a family owned and run company focused on developing long term relationships with customers that are looking for a true partner moving forward in their drug development CMC needs”, concludes Negrisoli.

For further information, please visit the Flamma website at <http://www.flammagroup.com>.

Contact Flamma

Kenneth Drew, Ph.D., VP Flamma USA
1-617-515-0975
ken.drew@flammagroup.com

About Flamma:

FLAMMA is a family owned & run, fully integrated CMO based in Bergamo (near Milan in Northern Italy) established in 1950.

FLAMMA is a company specialized in the cGMP manufacture of APIs, NCEs, RSMs, and advanced intermediates for the pharmaceutical industry. Flamma has particular expertise in high value chiral materials specifically amino acid related materials. Flamma also manufactures specialty compounds and advanced intermediates for the nutraceutical and cosmetic industries and has several generic products.

FLAMMA has five manufacturing facilities- Italy (3), China, and the USA. The cGMP Italian locations (Chignolo, Isso and recently acquired Bulciago) are regularly inspected by the FDA and AIFA. Flamma Honkai, located in Dalian, China, is a cGMP manufacturing facility that has been inspected by Chinese National Medical Products Administration (NMPA) formally known as the Chinese FDA. Flamma provides security when working in China with our 100% owned, self-managed facilities that deliver results without worry. Flamma reliably supplies materials directly to customers and/or delivers materials to its cGMP facilities in Italy in order to deliver the customer’s compound on-time and with the desired specifications. Flamma offers cost-effective services to customers looking for a trusted partner within China.

Flamma USA is located outside Philadelphia provides Flamma with the ability to service customers looking to keep materials in the USA for pre-clinical/early stage clinical development.



Being a fully integrated company allows Flamma to move your compounds quickly along their journey taking into consideration all aspects necessary for the success of your project.

Flamma can be of assistance for early stage pre-clinical development of small molecules as well as for large-scale commercial manufacturing. With a total reactor capacity of 1,100 m³ and over 700 employees, see why Flamma should be your next contract manufacturer. FLAMMA - THE THINKING CDMO™.

For more information, please visit www.flammagroup.com

<https://www.flammagroup.com/>

<https://www.linkedin.com/company/flamma-spa/>

<https://twitter.com/flammagroup>

<https://www.facebook.com/TheFlammaGroup/>